undefined undefined
NaN.000
NaN.00%
Innate Pharma press release (NASDAQ:IPHA): Q1 Revenues amounted to €6.6 million. Cash, cash equivalents and financial assets of the company amounted to €113.9 million as of March 31, 2024. More on Inn...
05-14 22:18
Gainers Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0....
04-01 20:08
Companies in the Healthcare sector have received a lot of coverage today as ana...
03-23 09:40
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
03-21 18:15
Sanofi to exercise one option to license a new ANKET® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization of the
2023-12-19 15:11
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5 price target.
2023-11-15 21:27
Financial Results: Cash, cash equivalents and financial assets of the Company amounted to €121.9 million as of September 30, 2023. At the same date, financial liabilities amounted to €40.3 million. Revenues
2023-11-14 14:49
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).
2023-10-05 20:19
What is the target price for Innate Pharma (IPHA)? The latest price target f...
2023-09-18 18:47